Foundation Medicine's Revenues Double as it Readies Hematological Cancer Panel | GenomeWeb

This story was originally published Nov. 8.

The newly-public Foundation Medicine saw its quarterly revenues more than double to $8.2 million in the third quarter compared to $3 million in the previous year's third quarter, and it's finalizing its second next-generation sequencing-based cancer panel for hematological malignancies, the company said this week.

"We see FoundationOne as our starting point, not the finish line," President and CEO Michael Pellini said during a conference call discussing the company's earnings.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.